Inhaled morphine for palliation of dyspnea in end-stage cystic fibrosis

American Journal of Health-System Pharmacy

Volumn 67, Issue 9, 2010, Pages 737-740

  Hayes Jr , Don ^a   Anstead, Michael I ^a   Warner, Rena T ^a   Kuhn, Robert J ^b   Ballard, Hubert O ^c  

^a Cleveland Clinic Lerner   (United States)

^b Department of Pharmacy Practice   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Albuterol; Antiinfective agents; Cystic fibrosis; Diluents; Dornase alfa; Drug administration; Drug administration routes; Dyspnea; Ipratropium bromide; Ketamine; Methadone; Morphine sulfate; Opiates; Oxycodone; Oxygen; Sodium chloride

Indexed keywords

DORNASE ALFA; FENTANYL; IPRATROPIUM BROMIDE; KETAMINE; METHADONE; MORPHINE SULFATE; OXYCODONE; OXYGEN; SALBUTAMOL SULFATE; SODIUM CHLORIDE; MORPHINE; NARCOTIC AGENT;

ADULT; ARTICLE; CASE REPORT; CYSTIC FIBROSIS; DETERIORATION; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; HUMAN; LUNG FUNCTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; OUTCOME ASSESSMENT; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; TERMINALLY ILL PATIENT;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DYSPNEA; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MORPHINE; NARCOTICS; OUTCOME ASSESSMENT (HEALTH CARE); PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TERMINALLY ILL;

EID: 77955064655     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp080188     Document Type: Article

References (23)

1. Bech B, Pressler T, Iversen M et al. Long-term outcome of lung transplantation for cystic fibrosis - Danish results. Eur J Cardiothorac Surg. 2004; 26:1180-6.
2. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008; 36:29-38.
3. Jankelson D, Hosseini K, Mather LE et al. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2270-4.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. www.nccn.org/ professionals/physician-gls/f-guidelines. asp#supportive (accessed 2010 Feb 2.)
5. Farncombe M, Chater S. Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage. 1993; 8:221-5. (Pubitemid 23148869)
6. Farncombe M, Chater S, Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994; 8:306-12.
7. Tooms A, McKenzie A, Grey H. Nebulised morphine. Lancet. 1993; 342:1123-4. Letter.
8. Stein WM, Min YK. Nebulized morphine for paroxysmal cough and dyspnea in a nursing home resident with metastatic cancer. Am J Hosp Palliat Care. 1997; 14:52-6.
9. Brown SJ, Eichner SF, Jones JR. Nebulized morphine for relief of dyspnea due to chronic lung disease. Ann Pharmacother. 2005; 39:1088-92.
10. Burdon JG, Juniper EF, Killian KJ et al. The perception of breathlessness in asthma. Am Rev Respir Dis. 1982; 126:825-8.
11. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996; 51:596-600.
12. Kanga J, Kuhn R, Craigmyle L et al. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther. 1999; 21:1343-56. (Pubitemid 29409278)
13. Robinson WM, Ravilly S, Berde C et al. End-of-life care in cystic fibrosis. Pediatrics. 1997; 100:205-9.
14. Janahi IA, Maciejewski SR, Teran JM et al. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatr Pulmonol. 2000; 30:257-9.
15. Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration. 2004; 71:646-9.
16. Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics. 2002; 110:e38.
17. Woodcock AA, Gross ER, Gellert A et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med. 1981; 305:1611-6.
18. Cabot PJ, Dodd PR, Cramond T et al. Characterization of non-conventional opioid binding sites in rat and human lung. Eur J Pharmacol. 1994; 268:247-55. (Pubitemid 2113173)
19. Cabot PJ, Cramond T, Smith MT. Quantitative autoradiography of peripheral opioid binding sites in rat lung. Eur J Pharmacol. 1996; 310:47-53.
20. Cabot PJ, Cramond T, Smith MT. Morphine has a dual concentration- dependent effect on K(+)-evoked substance P release from rat peripheral airways. Pulm Pharmacol Ther. 1997; 10:215-21.
21. Kudlacz EM, Logan DE, Shatzer SA et al. Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by NK1 and NK2 receptor antagonists. Eur J Pharmacol. 1993; 241:17-25.
22. Masood AR, Thomas SH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996; 41:250-2.
23. Chrubasik J, Wüst H, Friedrich G et al. Absorption and bioavailability of nebulized morphine. Br J Anaesth. 1988; 61:228-30.